Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06409624 Recruiting - Clinical trials for Pulmonary Hypertension

Association Between Biomarkers and eGFR Decline in Pulmonary Hypertension

Start date: May 2024
Phase:
Study type: Observational

The objective of this study is to examine the association between urinary and plasma biomarkers and the change of estimated glomerular filtration rate (eGFR) in patients with pulmonary hypertension (PH) as a tool to identify patients at high risk for short-term eGFR decline.

NCT ID: NCT06406192 Recruiting - Hypertension Clinical Trials

Effects of FOR-Care Model on Preventive Medicine

Start date: March 11, 2024
Phase: N/A
Study type: Interventional

This study aims to address the prevalence of undiagnosed hypertension and diabetes by assessing the impact of the FOR-Care model on preventive medicine. The model focuses on improving the documentation of blood pressure, height, and weight in outpatient settings. Through a cluster randomized trial at National Taiwan University Hospital, clinics will either implement the FOR-Care model or continue with usual care. The trial will evaluate the effectiveness of the intervention in documenting these measurements and its impact on diagnosing hypertension and diabetes. The outcomes will provide valuable insights into enhancing preventive medicine and improving care for chronic diseases.

NCT ID: NCT06405126 Recruiting - Clinical trials for Pulmonary Hypertension

Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension

Optiek 2-0
Start date: February 21, 2024
Phase:
Study type: Observational

In this study the diagnostic accuracy of a diagnostic tool for the diagnosis of post-capillary pulmonary hypertension will be investigated. The diagnostic tool was designed based on artificial intelligence, using machine learning on a database of 344 patients with group 1 or group 2 pulmonary hypertension. The tool uses 20 non-invasive parameters which are derived from laboratory results, ECG, echocardiography and spirometry. Based on these parameters, the predictive tool estimates the probability of group 2 pulmonary hypertension. During this clinical study, patients with an intermediate or high suspicion of pulmonary hypertension, with an indication for a diagnostic right heart catheterization, will be included. Patients with risk factors for group 3, 4 or 5 pulmonary hypertension will be excluded. The necessary parameters to run the predictive model will be extracted from the patients medical file. Patients will undergo a standard of care right heart catheterization (gold standard). Afterwards the results of the predictive model will be compared to those of the right heart catheterization, to allow the assessment of the sensitivity, specificity, positive and negative predictive value of the predictive tool.

NCT ID: NCT06401759 Recruiting - Hypertension Clinical Trials

Use of Podcasts in the Education of Hypertension Patients

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

Hypertension is an important public health problem all over the world due to its high prevalence and its association with increased risk of cardiovascular disease. At the same time, it is a condition in which acquired factors, genetic and metabolic disorders, characterized by increased intra-arterial blood pressure, occur together . According to the World Health Organization, hypertension is defined as systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or above According to the Arterial Hypertension Management 2018 Implementation Guide of the European Society of Cardiology and the European Society of Hypertension, it is estimated that there are more than 1 billion hypertension patients in the world and this number will reach 1.5 billion by 2025. In our country, there are approximately 20 million individuals with hypertension. It is thought to be Hypertension treatment is a lifelong process that includes lifestyle changes and patient education along with medical treatment.Turkish Endocrinology and Metabolism. The aim of hypertension treatment is to ensure that blood pressure decreases to the targeted level, to minimize target organ damage and complications caused by hypertension, to eliminate symptoms and reduce drug side effects, to ensure patient compliance with treatment and to provide self-management skills by enabling the patient to take an active role in his own treatment. The concept of self-management; It includes providing individuals with knowledge and skills regarding disease management, providing support to maintain the individual's self-care, supporting the decision-making process, and helping to recognize and cope with problems. The main goal in hypertension treatment is to control the patient's blood pressure. Achieving and maintaining self-management is also one of the most effective factors in controlling blood pressure. Inadequately treated and low self-management In hypertension patients, blood pressure control is inadequate and health risks increase. Therefore, all strategies implemented to increase self-management in hypertension patients also have positive effects on the individual's blood pressure control and disease prognosis.

NCT ID: NCT06401278 Recruiting - Hypertension Clinical Trials

Trans Cutaneous Electrical Acupoint Stimulation Versus TENS On Blood Pressure In Primary Hypertension Patients

Start date: May 5, 2024
Phase: N/A
Study type: Interventional

To compare between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension BACKGROUND: The current American College of Cardiology and the American Heart Association (ACC/AHA) 2017 guidelines define hypertension as systolic BP (SBP) of ≥130 mmHg or diastolic BP (DBP) of ≥80 mmHg. In adults, an increase of 20 mmHg in SBP or 10 mmHg in DBP is associated with more than a two-fold increase in mortality owing to stroke and other cardiovascular diseases. Hypertension accounts for 13% of premature deaths worldwide and is the third leading cause of disability-adjusted life years (Shah et al., 2022). Transcutaneous electrical nerve stimulation of the Neiguan (P6) point with acupressure is possibly affecting the blood pressure by protecting the myocardial tissues and influencing the nervous system through regulating the autonomic nervous system function and reduction in sympathetic activity. (Hassanein et al., 2021). HYPOTHESES There will be no a significant difference between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension RESEARCH QUESTION: Is there a significant difference between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension? Evaluating equipment, pre-post intervension outcomes: 1. BP by Digital Sphygmomanometer 2. quality of life by The SF-12 health status questionnaire 3. nitric oxide level in blood by nitric Oxide analysis. 4. sleep quality. by Pittsburgh Sleep Quality Index (PSQI) 5. exercise capacity and endurance by Thirty-Second Sit-To-Stand Test (30 STST)

NCT ID: NCT06394934 Recruiting - Hypertension Clinical Trials

Home Blood Pressure Variability and Its Link to Arteriosclerosis and Metabolic Dysfunction in Hypertensive Patients

Start date: January 9, 2024
Phase:
Study type: Observational [Patient Registry]

This observational study investigates the correlation between home blood pressure variability (BPV) and arteriosclerosis, alongside metabolic indicators, in hypertensive patients over a three-year period. The research specifically focuses on the predictive value of home BPV for major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and heart failure hospitalizations. Utilizing a mobile application called Healthscan for daily BP monitoring, the study aims to enhance the understanding of how BPV impacts cardiovascular and metabolic health in a real-world setting.

NCT ID: NCT06383858 Recruiting - Preeclampsia Clinical Trials

The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center

Start date: August 1, 2023
Phase:
Study type: Observational

Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery. Therefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance.

NCT ID: NCT06377878 Recruiting - Preeclampsia Clinical Trials

The Preeclampsia Registry

TPR
Start date: September 1, 2013
Phase:
Study type: Observational [Patient Registry]

The purpose of The Preeclampsia Registry is to collect and store medical and other information from women who have been medically diagnosed with preeclampsia or a related hypertensive (high blood pressure) disorder of pregnancy such as eclampsia or HELLP syndrome, their family members, and women who have not had preeclampsia to serve as controls. Information from participants will be used for medical research to try to understand why preeclampsia occurs, how to predict it better, and to develop experimental clinical trials of new treatments. The Registry will consist of a web-based survey and mechanism for collecting and reviewing medical records. This data will be utilized for immediate investigator-driven cross-sectional research projects (after proposal review by the Registry's scientific advisory board and as directed by the PI). Participants may also choose to be contacted regarding possible participation in future studies, about providing a biospecimen, as well as investigator-driven clinical trials. The Registry is anticipated to exist long-term and to serve as a foundation of participants from which to draw for studies of preeclampsia, anticipated to evolve as our scientific understanding of preeclampsia evolves.

NCT ID: NCT06374277 Recruiting - Stroke Clinical Trials

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

MedAAAction
Start date: April 6, 2024
Phase: N/A
Study type: Interventional

Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.

NCT ID: NCT06372470 Recruiting - Clinical trials for Uncomplicated Hypertension

Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment

OptiZest
Start date: April 15, 2024
Phase:
Study type: Observational

A pragmatic observational proof-of-concept study which aims to determine the feasibility of a remote titration clinic, assisted by home blood pressure monitoring and digital solutions, and assess its impact on real-world outcomes. By incorporating home blood pressure monitoring, the study seeks to offer a promising solution for personalised drug titration and self-management, potentially enhancing patient outcomes while optimising Zestril utilisation